Raymond James Financial Inc. Takes Position in Amedisys, Inc. (NASDAQ:AMED)

Raymond James Financial Inc. acquired a new position in Amedisys, Inc. (NASDAQ:AMED) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 2,372 shares of the health services provider’s stock, valued at approximately $215,000.

Several other institutional investors and hedge funds also recently bought and sold shares of AMED. Charles Schwab Investment Management Inc. lifted its position in shares of Amedisys by 4.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 361,812 shares of the health services provider’s stock worth $32,849,000 after acquiring an additional 15,730 shares in the last quarter. SRS Capital Advisors Inc. raised its stake in shares of Amedisys by 2,298.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,319 shares of the health services provider’s stock valued at $120,000 after purchasing an additional 1,264 shares during the period. US Bancorp DE lifted its holdings in Amedisys by 5.7% during the 4th quarter. US Bancorp DE now owns 3,916 shares of the health services provider’s stock worth $356,000 after purchasing an additional 210 shares in the last quarter. Amalgamated Bank boosted its stake in Amedisys by 2.9% in the 4th quarter. Amalgamated Bank now owns 15,593 shares of the health services provider’s stock worth $1,416,000 after purchasing an additional 444 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Amedisys by 22.6% during the 4th quarter. Bank of New York Mellon Corp now owns 298,870 shares of the health services provider’s stock valued at $27,134,000 after buying an additional 55,073 shares in the last quarter. 94.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a research report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Amedisys currently has a consensus rating of “Hold” and a consensus price target of $101.00.

Amedisys Trading Up 0.0 %

Shares of AMED stock opened at $91.51 on Friday. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The business’s fifty day moving average is $92.20 and its 200 day moving average is $92.05. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company has a market capitalization of $3.00 billion, a PE ratio of 36.31, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. On average, equities research analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.